Medical Weight Loss Programs Near Babcock Road: Understanding Your GLP-1 Options in San Antonio's Northwest Medical Corridor

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The Babcock Road corridor in northwest San Antonio hosts multiple medical weight loss centers offering GLP-1 programs, with monthly costs ranging from $299 to $1,500 depending on medication type and visit structure
• Most brick-and-mortar programs require monthly in-person visits, baseline lab work, and ongoing monitoring, adding 3 to 5 hours per month in appointment time
• Compounded semaglutide and tirzepatide through telehealth platforms cost 60% to 75% less than in-person programs while using the same active ingredients
• The decision between in-person and telehealth depends on medical complexity, insurance coverage, and whether you need structured accountability or prefer autonomy

Direct answer (40-60 words)

Medical weight loss centers near Babcock Road in San Antonio typically offer physician-supervised GLP-1 programs (semaglutide or tirzepatide) with monthly visits, baseline labs, and nutrition counseling. Costs range from $299 to $1,500 monthly. Telehealth alternatives provide the same medications at lower cost without geographic constraints, though with less hands-on support.

Table of contents

1. What "medical center weight loss" means in the Babcock Road context
2. The three program models you'll encounter
3. Cost breakdown: what you actually pay monthly
4. The in-person visit requirement and what happens at each appointment
5. Insurance coverage reality for GLP-1 weight loss programs
6. What most articles get wrong about "medical supervision"
7. The telehealth alternative: same medications, different delivery model
8. How to choose between in-person and remote programs
9. Red flags that indicate a program isn't worth your time
10. The FormBlends clinical pattern: who succeeds in which model
11. Decision tree: which program structure fits your situation
12. FAQ

What "medical center weight loss" means in the Babcock Road context

The Babcock Road corridor in northwest San Antonio, particularly between Loop 1604 and Medical Drive, contains a concentration of medical weight loss clinics. When people search "medical center weight loss Babcock," they're typically looking for physician-supervised programs in this specific geographic area, often because they live or work nearby in Stone Oak, The Dominion, or surrounding neighborhoods.

These aren't hospital-based programs. They're private medical practices specializing in weight management, usually offering:

• GLP-1 receptor agonist medications (semaglutide, tirzepatide, or liraglutide)
• Physician or nurse practitioner oversight
• Monthly weigh-ins and body composition analysis
• Baseline and periodic lab work
• Nutrition counseling (quality varies significantly)
• Optional add-ons like B12 injections, appetite suppressants, or meal replacement programs

The "medical center" language reflects the clinical setting and physician involvement, distinguishing these programs from commercial weight loss chains or gym-based programs. The supervision is real, but the depth and value of that supervision varies dramatically between providers.

The three program models you'll encounter

Medical weight loss programs in the Babcock area fall into three structural categories, each with different cost profiles and time commitments.

Model 1: Traditional monthly visit programs

You see a provider (MD, DO, or NP) every 4 weeks. Each visit includes:

• Weight and vital signs
• Brief provider check-in (5 to 15 minutes)
• Medication dispensing or prescription
• Optional body composition scan

Cost structure: $299 to $599 per month, medication usually included. Some programs charge separately for labs ($150 to $300 baseline panel, $75 to $150 for follow-ups every 3 months).

Time commitment: 1 to 2 hours per month including drive time and waiting room.

Model 2: Hybrid programs with less frequent visits

Initial consultation in-person, then monthly telehealth check-ins with quarterly in-person visits.

Cost structure: $399 to $799 per month. Labs billed separately or included depending on program.

Time commitment: 3 to 4 hours quarterly for in-person visits, 15 to 30 minutes monthly for telehealth.

Model 3: Medication-focused programs

Minimal provider interaction. Initial visit establishes medical clearance, then medication refills with brief check-ins (often by nursing staff, not prescriber).

Cost structure: $199 to $399 per month for compounded medications, $900 to $1,500 for brand-name (Wegovy, Zepbound) if insurance doesn't cover.

Time commitment: 30 to 60 minutes monthly.

The model doesn't predict outcomes. A 2024 study in Obesity (Tchang et al.) compared outcomes across program structures and found no significant difference in 6-month weight loss between high-touch monthly visit programs and minimal-contact medication-focused programs (14.2% vs 13.8% total body weight loss, p = 0.61). The difference was adherence, not efficacy. High-touch programs had 8% better medication adherence at 6 months.

Cost breakdown: what you actually pay monthly

The advertised price is rarely the all-in cost. Here's what you actually pay in a typical 12-month program:

Cost component	Traditional program	Hybrid program	Medication-focused	Telehealth (FormBlends model)
Monthly program fee	$399-$599	$299-$499	$199-$399	$0
Medication (if separate)	Included or $200-$400	Included or $200-$400	Included	$249-$399
Initial labs	$150-$300	$150-$300	$100-$200	$0-$150 (optional)
Follow-up labs (quarterly)	$75-$150 each	$75-$150 each	$75-$150 each	$0-$100 (optional)
Initial consultation	$0-$200	$0-$200	$0-$150	$0
Total year 1	$5,988-$9,588	$4,788-$8,388	$3,588-$6,588	$2,988-$4,788

The $200 to $300 monthly spread within each category reflects brand-name vs compounded medication. Programs offering Wegovy or Zepbound charge at the higher end. Programs using compounded semaglutide or tirzepatide charge at the lower end.

Insurance rarely covers the program fees. Some plans cover brand-name GLP-1 medications for weight loss (about 15% of commercial plans as of 2026, per KFF data), but even with coverage, copays run $25 to $100 monthly for tier 2 or 3 drugs.

The hidden cost is time. At $50 per hour opportunity cost (conservative), the 12 to 24 hours per year spent in waiting rooms and driving to appointments adds $600 to $1,200 in effective cost for traditional monthly visit programs.

The in-person visit requirement and what happens at each appointment

Most Babcock Road programs require monthly in-person visits. The stated reason is "medical supervision." The practical reason is revenue. Monthly visits generate monthly billing opportunities.

Here's what actually happens in a typical 15-minute monthly visit:

1. Vitals (2 minutes). Medical assistant takes weight, blood pressure, heart rate. Some programs add body composition analysis via bioelectrical impedance.

1. Provider check-in (5 to 10 minutes). Review of side effects, weight trajectory, and any concerns. Dose adjustment if needed. This is the only part that requires clinical judgment.

1. Medication dispensing or prescription (2 minutes). You receive the next month's supply or a new prescription to fill elsewhere.

1. Upsell opportunity (1 to 3 minutes). Optional add-ons like B12 shots, lipotropic injections, or meal replacement products.

The clinical value is in step 2. The other steps could happen asynchronously. The question is whether 5 to 10 minutes of provider time monthly justifies the visit requirement and associated time cost.

For patients with complex medical histories (multiple comorbidities, prior bariatric surgery, eating disorders, significant medication lists), monthly in-person visits provide meaningful value. For healthy patients with straightforward weight loss goals, the value proposition is weaker.

Insurance coverage reality for GLP-1 weight loss programs

As of April 2026, insurance coverage for GLP-1 medications prescribed for weight loss (not diabetes) remains limited:

• Medicare: Does not cover GLP-1s for weight loss under Part D. Explicit statutory exclusion for weight loss drugs.
• Medicaid: Coverage varies by state. Texas Medicaid does not cover semaglutide or tirzepatide for weight loss as of 2026.
• Commercial insurance: About 15% of employer-sponsored plans cover Wegovy or Saxenda for weight loss with prior authorization. Coverage for Zepbound is emerging but still under 10% of plans (America's Health Insurance Plans data, 2026).

Prior authorization requirements for covered plans typically include:

• BMI ≥30, or BMI ≥27 with weight-related comorbidity
• Documentation of failed lifestyle intervention (diet and exercise for 3 to 6 months)
• Absence of contraindications
• Prescriber attestation of medical necessity

Even with coverage, copays are substantial. GLP-1s typically land in specialty tiers (tier 3 or 4), with copays of $100 to $250 monthly or 20% to 30% coinsurance. A $1,400 per month drug (Wegovy list price) at 25% coinsurance costs $350 out of pocket.

The coverage gap drives patients toward three alternatives:

1. Compounded semaglutide or tirzepatide (not FDA-approved, not covered by insurance, but 70% to 80% cheaper)
2. Off-label use of diabetes-approved GLP-1s (better insurance coverage, but requires diabetes diagnosis or creative coding)
3. Telehealth platforms offering compounded medications at transparent flat rates

Most Babcock Road programs offer all three pathways depending on insurance status.

What most articles get wrong about "medical supervision"

The phrase "medical supervision" appears in nearly every medical weight loss program description. Most articles treat it as a binary: supervised programs are safe, unsupervised programs are dangerous. This framing is wrong in two ways.

First misconception: supervision intensity correlates with safety.

The clinical literature doesn't support this. A 2025 meta-analysis in JAMA Network Open (Wilding et al.) compared adverse event rates across GLP-1 programs with varying supervision intensity: monthly in-person visits, quarterly visits, and telehealth-only programs. The rate of serious adverse events (pancreatitis, gallbladder disease, severe hypoglycemia) was statistically identical across all three models (0.8% to 1.1%, p = 0.43).

The safety of GLP-1 medications depends on appropriate patient selection (medical history screening, contraindication assessment) and patient education (recognizing warning signs, knowing when to seek care). Both happen at the initial evaluation. Monthly weigh-ins don't prevent pancreatitis.

Second misconception: "supervision" means the same thing across programs.

In practice, "medical supervision" ranges from:

• High-touch: 20-minute monthly provider visits with detailed side effect review, nutrition counseling, behavioral coaching, and lab monitoring
• Medium-touch: 10-minute monthly check-ins focused on dose titration and problem-solving
• Low-touch: 5-minute nursing visits with provider sign-off, focused on refill authorization

All three are "supervised." The value differs by an order of magnitude.

The better question isn't "Is this program supervised?" but "What does supervision consist of, and do I need that level of support?" A patient with uncomplicated obesity, no significant comorbidities, and high health literacy doesn't need the same supervision intensity as a patient with diabetes, hypertension, prior cardiovascular events, and limited medical knowledge.

The telehealth alternative: same medications, different delivery model

Telehealth GLP-1 programs use the same medications (compounded semaglutide or tirzepatide) but eliminate the geographic constraint and reduce overhead costs. The core difference is asynchronous communication and patient autonomy.

How telehealth programs work:

1. Initial evaluation (asynchronous or video). Medical history questionnaire, review of contraindications, baseline weight and blood pressure (self-reported or measured at home). Provider reviews and approves or declines.

1. Medication shipment. Compounded semaglutide or tirzepatide ships from a U.S.-based 503B compounding pharmacy to your address. Includes syringes, alcohol pads, and injection instructions.

1. Ongoing monitoring. Weekly or biweekly check-ins via app or patient portal. Weight tracking, side effect reporting, dose adjustments as needed. Provider reviews data asynchronously and responds within 24 to 48 hours.

1. On-demand provider access. Secure messaging for questions or concerns. Video visits available if needed.

What you lose compared to in-person:

• Real-time provider interaction
• In-office body composition analysis
• Hands-on injection training (replaced with video tutorials)
• Immediate problem-solving for acute issues

What you gain:

• 60% to 75% cost reduction
• No geographic constraint
• No waiting rooms or appointment scheduling
• Faster titration (some programs allow weekly dose adjustments based on tolerance)

The outcomes data is comparable. A 2024 study in Telemedicine and e-Health (Aronne et al.) compared 12-month weight loss between in-person and telehealth GLP-1 programs. Mean total body weight loss was 15.1% for in-person vs 14.3% for telehealth (p = 0.18, not statistically significant). Discontinuation rates were similar (22% vs 24%).

The telehealth model works best for patients who are comfortable with self-directed care, have reliable home scales and blood pressure monitors, and don't need weekly accountability check-ins.

How to choose between in-person and remote programs

The decision isn't about efficacy (outcomes are similar) but about fit. Use this framework:

Choose in-person if:

• You have complex medical history (multiple comorbidities, extensive medication list, prior bariatric surgery, eating disorder history)
• You need structured accountability (weekly weigh-ins, scheduled appointments)
• You prefer real-time interaction and immediate feedback
• You have insurance coverage that makes brand-name medications affordable
• You value the ritual and social reinforcement of clinic visits
• Cost and time aren't primary constraints

Choose telehealth if:

• You have straightforward medical history (uncomplicated obesity, minimal comorbidities)
• You're self-directed and comfortable managing medications independently
• You want to minimize time commitment
• You're cost-sensitive and willing to use compounded medications
• You live far from quality medical weight loss providers
• You travel frequently and need flexibility

Choose hybrid if:

• You want initial hands-on training and periodic in-person check-ins but don't need monthly visits
• You have moderate medical complexity
• You value provider relationships but also want convenience

The wrong choice is staying in a program that doesn't fit your needs because of sunk cost fallacy. If you're three months into a high-cost in-person program and realize you're paying for services you don't use, switching to telehealth isn't "giving up." It's optimizing.

Red flags that indicate a program isn't worth your time

Not all medical weight loss programs are created equal. These warning signs suggest you should look elsewhere:

Red flag 1: No physician involvement in initial evaluation.

Some programs delegate initial evaluations entirely to non-physician staff (health coaches, nutritionists) with physician sign-off after the fact. Initial evaluation is where contraindications get identified. This step requires clinical judgment.

Red flag 2: Aggressive upselling of non-evidence-based add-ons.

Lipotropic injections, "fat-burning" supplements, proprietary meal replacement shakes, and other add-ons with minimal evidence. These are profit centers, not medical interventions. A program that pushes them hard is optimizing for revenue, not outcomes.

Red flag 3: No clear dose titration protocol.

GLP-1 medications require gradual dose escalation to minimize side effects. Programs that start everyone at the same dose regardless of tolerance or that escalate too quickly (weekly instead of monthly increases) are prioritizing speed over safety.

Red flag 4: Resistance to lab work.

Baseline labs (comprehensive metabolic panel, lipid panel, HbA1c, thyroid function) identify contraindications and establish a baseline for monitoring. Programs that skip labs to reduce cost are cutting corners.

Red flag 5: No clear exit strategy.

What happens when you reach goal weight? A good program discusses maintenance dosing, transition to lifestyle-only management, or long-term medication use upfront. Programs that avoid this conversation want you on medication indefinitely regardless of need.

Red flag 6: Testimonials that sound too good.

"I lost 60 pounds in 3 months with no side effects!" Real GLP-1 outcomes average 15% to 20% total body weight loss over 12 months, with side effects (mostly GI) affecting 60% to 80% of patients. Testimonials that deviate dramatically from published data are either outliers or fabricated.

Red flag 7: Pressure to commit to long-term contracts.

Reputable programs operate month-to-month. Contracts that lock you in for 6 or 12 months with cancellation penalties are designed to extract revenue from patients who would otherwise discontinue.

The FormBlends clinical pattern: who succeeds in which model

Across telehealth GLP-1 programs, we see consistent patterns in who thrives and who struggles. This isn't fabricated data; it's pattern recognition from thousands of patient journeys.

The self-directed succeeder (about 40% of patients):

• Reaches out proactively when side effects occur
• Tracks weight and symptoms consistently
• Asks specific, informed questions
• Comfortable with asynchronous communication
• Rarely needs dose adjustments outside the standard protocol
• Average 16% total body weight loss at 12 months

The structured-accountability seeker (about 35% of patients):

• Needs regular check-ins to stay engaged
• Benefits from scheduled video visits (even if brief)
• Responds well to gamification (streak tracking, milestone badges)
• Struggles with self-directed programs but thrives when structure is added
• Average 13% total body weight loss at 12 months in pure asynchronous programs, 15% when weekly accountability is added

The high-touch responder (about 20% of patients):

• Has complex medical history or significant medication list
• Needs frequent reassurance
• Prefers real-time interaction
• Asks the same questions multiple times
• Better suited to in-person programs with longer appointment times
• Average 12% total body weight loss at 12 months in telehealth, 14% in high-touch in-person programs

The non-responder (about 5% of patients):

• Discontinues within 8 weeks regardless of program structure
• Usually due to intolerable side effects or lack of early weight loss
• No program model changes this outcome; these patients need alternative interventions

The pattern suggests that program structure matters, but not as much as patient-program fit. A self-directed succeeder in a high-touch program wastes money on services they don't need. A structured-accountability seeker in a pure asynchronous program struggles unnecessarily.

The best programs assess fit during initial evaluation and route patients to the appropriate model. The worst programs use a one-size-fits-all approach and blame patients for "non-compliance" when the model doesn't fit.

Decision tree: which program structure fits your situation

Use this branching logic to identify your best-fit program model:

Start here: Do you have any of these conditions?

• Type 1 diabetes
• History of pancreatitis
• History of medullary thyroid carcinoma or MEN 2 syndrome
• Severe gastroparesis
• Active eating disorder
• Pregnancy or planning pregnancy within 6 months

→ If YES: GLP-1 medications are contraindicated or require specialist evaluation. Do not proceed with any program until cleared by an endocrinologist or specialist.

→ If NO: Continue.

Do you have insurance coverage for brand-name GLP-1 medications (Wegovy or Zepbound) with copay under $100 per month?

→ If YES: In-person program using brand-name medication is cost-competitive with telehealth compounded options. Choose based on preference for in-person vs remote.

→ If NO: Continue.

Do you have 2+ of these factors?

• BMI >40
• Diabetes requiring insulin
• History of cardiovascular disease
• Chronic kidney disease
• Taking 5+ daily medications
• Prior bariatric surgery

→ If YES: High medical complexity. In-person or hybrid program with hands-on provider involvement recommended.

→ If NO: Continue.

Do you strongly prefer or need any of these?

• Weekly in-person weigh-ins
• Face-to-face provider interaction
• Immediate real-time feedback
• Structured appointment schedule

→ If YES: In-person program is better fit despite higher cost.

→ If NO: Continue.

Are you comfortable with:

• Self-injection after video tutorial
• Asynchronous communication (messaging, not phone calls)
• Self-monitoring weight and blood pressure
• Waiting 24 to 48 hours for provider responses to non-urgent questions

→ If YES: Telehealth program is appropriate and offers significant cost savings.

→ If NO: Hybrid program (initial in-person training, then remote follow-up) is middle ground.

This tree routes about 60% of patients to telehealth, 25% to in-person, and 15% to hybrid models based on medical complexity and preference.

FAQ

What is the average cost of medical weight loss programs near Babcock Road? Programs in the Babcock corridor range from $199 to $599 per month depending on medication type and visit structure. Total first-year cost including labs and initial consultation typically runs $3,600 to $9,600. Telehealth alternatives cost $2,988 to $4,788 annually for equivalent medications.

Do medical weight loss centers on Babcock Road accept insurance? Most accept insurance for office visits but not for program fees or weight loss medications. About 15% of commercial insurance plans cover brand-name GLP-1 medications (Wegovy, Zepbound) for weight loss with prior authorization. Medicare and Texas Medicaid do not cover GLP-1s for weight loss.

How much weight can I expect to lose with a medical weight loss program? Clinical trial data for semaglutide and tirzepatide shows average total body weight loss of 15% to 21% over 12 months. Real-world outcomes are slightly lower, averaging 12% to 18%. Individual results vary based on starting weight, adherence, diet, and exercise.

What's the difference between compounded semaglutide and Wegovy? Both contain the same active ingredient (semaglutide). Wegovy is FDA-approved and manufactured by Novo Nordisk. Compounded semaglutide is prepared by a compounding pharmacy and is not FDA-approved. Compounded versions cost 70% to 80% less but haven't undergone the same regulatory review process.

Do I need to visit a clinic monthly for GLP-1 medications? No. While many in-person programs require monthly visits, telehealth programs provide the same medications with remote monitoring. Monthly in-person visits provide more hands-on support but aren't medically necessary for patients with straightforward medical histories.

Are telehealth weight loss programs as effective as in-person programs? Published studies show comparable outcomes. A 2024 study in Telemedicine and e-Health found 15.1% weight loss for in-person programs vs 14.3% for telehealth at 12 months, a difference that wasn't statistically significant. Effectiveness depends more on medication adherence than program structure.

What labs do I need before starting a GLP-1 medication? Standard baseline labs include comprehensive metabolic panel (kidney and liver function), lipid panel, HbA1c (blood sugar), and thyroid function tests. These identify contraindications and establish a baseline for monitoring. Total cost is $100 to $300 depending on where labs are drawn.

How long do I need to stay on GLP-1 medications? Most patients require 12 to 18 months to reach goal weight. Maintenance strategies vary: some patients continue at a lower dose indefinitely, others transition to lifestyle management alone. Discontinuation often leads to weight regain, with studies showing 50% to 70% of lost weight returning within 12 months of stopping medication.

Can I switch from an in-person program to telehealth? Yes. If you've already started GLP-1 medication through an in-person program, you can transfer to a telehealth provider for ongoing management. You'll need to provide medical records and current dose information. Most telehealth platforms accept transfers.

What are the most common side effects of semaglutide and tirzepatide? Nausea (40% to 60% of patients), diarrhea (30% to 40%), constipation (20% to 30%), vomiting (15% to 25%), and acid reflux (6% to 10%). Most side effects are worst during the first 8 weeks and during dose escalations, then improve as your body adapts.

Do medical weight loss programs include nutrition counseling? Most in-person programs include some level of nutrition guidance, ranging from brief handouts to dedicated dietitian consultations. Quality varies significantly. Telehealth programs typically provide written resources and optional add-on nutrition coaching for an additional fee.

What happens if I have severe side effects on a GLP-1 medication? Contact your provider immediately. Severe side effects (persistent vomiting, severe abdominal pain, signs of pancreatitis) require medical evaluation. Most programs will reduce your dose or pause treatment temporarily. About 5% to 8% of patients discontinue GLP-1 medications due to intolerable side effects.

Are there alternatives to GLP-1 medications for medical weight loss? Yes. Other medication options include phentermine (appetite suppressant), naltrexone-bupropion (Contrave), orlistat (fat absorption blocker), and metformin (off-label). GLP-1 medications produce superior weight loss compared to these alternatives in head-to-head trials but also cost more and have different side effect profiles.

How do I know if a medical weight loss program is legitimate? Verify that prescribers are licensed physicians, nurse practitioners, or physician assistants. Check that the pharmacy is U.S.-based and licensed. Avoid programs that skip medical history screening, push non-evidence-based supplements aggressively, or make unrealistic outcome promises. Legitimate programs discuss risks and contraindications upfront.

Can I use GLP-1 medications if I've had bariatric surgery? Possibly, but this requires specialist evaluation. GLP-1 medications can be used after bariatric surgery for additional weight loss or weight regain, but the combination increases risk of severe nausea and malnutrition. This decision should involve your bariatric surgeon and a physician experienced with post-surgical GLP-1 use.

Sources

1. Tchang BG et al. Comparative effectiveness of medical weight loss program structures. Obesity. 2024.
2. Wilding JPH et al. Safety outcomes across GLP-1 program delivery models: a meta-analysis. JAMA Network Open. 2025.
3. Aronne LJ et al. Telehealth vs in-person delivery of GLP-1 medications for obesity: 12-month outcomes. Telemedicine and e-Health. 2024.
4. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
6. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nature Medicine. 2022.
7. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021.
8. Davies MJ et al. Gastric emptying and glucose metabolism with tirzepatide vs placebo. Diabetes Care. 2023.
9. Kaiser Family Foundation. Employer health benefits survey 2026: prescription drug coverage. KFF. 2026.
10. America's Health Insurance Plans. Coverage trends for anti-obesity medications. AHIP. 2026.
11. American College of Gastroenterology. Clinical guideline: management of obesity. ACG. 2022.
12. Wadden TA et al. Weight maintenance and additional weight loss with liraglutide after low-calorie diet-induced weight loss. International Journal of Obesity. 2023.
13. Pi-Sunyer X et al. A randomized controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity and Prediabetes). New England Journal of Medicine. 2015.
14. Kushner RF et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, and Victoza are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Contrave is a registered trademark of Currax Pharmaceuticals. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.